These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 25756635)
1. Response to Granoff. Rothbaum BO; Ressler K Am J Psychiatry; 2014 Nov; 171(11):1222. PubMed ID: 25756635 [No Abstract] [Full Text] [Related]
2. The impact of benzodiazepine management in the randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy. Granoff AL Am J Psychiatry; 2014 Nov; 171(11):1222. PubMed ID: 25756634 [No Abstract] [Full Text] [Related]
3. Response to Smith. Rothbaum BO; Price M; Ressler K Am J Psychiatry; 2014 Nov; 171(11):1223-4. PubMed ID: 25756637 [No Abstract] [Full Text] [Related]
4. Pharmacologic augmentation of extinction learning during exposure therapy for PTSD. Neylan TC Am J Psychiatry; 2014 Jun; 171(6):597-9. PubMed ID: 24880503 [No Abstract] [Full Text] [Related]
5. Possible negative effects of extinction learning on outcomes for patients receiving exposure therapy. Smith E Am J Psychiatry; 2014 Nov; 171(11):1222-3. PubMed ID: 25756636 [No Abstract] [Full Text] [Related]
6. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Rothbaum BO; Price M; Jovanovic T; Norrholm SD; Gerardi M; Dunlop B; Davis M; Bradley B; Duncan EJ; Rizzo A; Ressler KJ Am J Psychiatry; 2014 Jun; 171(6):640-8. PubMed ID: 24743802 [TBL] [Abstract][Full Text] [Related]
7. In session extinction and outcome in Virtual Reality Exposure Therapy for PTSD. Rauch SAM; Koola C; Post L; Yasinski C; Norrholm SD; Black K; Rothbaum BO Behav Res Ther; 2018 Oct; 109():1-9. PubMed ID: 30059794 [TBL] [Abstract][Full Text] [Related]
8. Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy. Norrholm SD; Jovanovic T; Gerardi M; Breazeale KG; Price M; Davis M; Duncan E; Ressler KJ; Bradley B; Rizzo A; Tuerk PW; Rothbaum BO Behav Res Ther; 2016 Jul; 82():28-37. PubMed ID: 27183343 [TBL] [Abstract][Full Text] [Related]
9. An investigation of outcome expectancies as a predictor of treatment response for combat veterans with PTSD: comparison of clinician, self-report, and biological measures. Price M; Maples JL; Jovanovic T; Norrholm SD; Heekin M; Rothbaum BO Depress Anxiety; 2015 Jun; 32(6):392-9. PubMed ID: 25703611 [TBL] [Abstract][Full Text] [Related]
10. Investigating Relationships Between PTSD Symptom Clusters Within Virtual Reality Exposure Therapy for OEF/OIF Veterans. Maples-Keller JL; Price M; Rauch S; Gerardi M; Rothbaum BO Behav Ther; 2017 Mar; 48(2):147-155. PubMed ID: 28270326 [TBL] [Abstract][Full Text] [Related]
11. A Randomized, Head-to-Head Study of Virtual Reality Exposure Therapy for Posttraumatic Stress Disorder. McLay RN; Baird A; Webb-Murphy J; Deal W; Tran L; Anson H; Klam W; Johnston S Cyberpsychol Behav Soc Netw; 2017 Apr; 20(4):218-224. PubMed ID: 28394217 [TBL] [Abstract][Full Text] [Related]
12. Extinction learning as a moderator of d-cycloserine efficacy for enhancing exposure therapy in posttraumatic stress disorder. de Kleine RA; Smits JA; Hendriks GJ; Becker ES; van Minnen A J Anxiety Disord; 2015 Aug; 34():63-7. PubMed ID: 26121495 [TBL] [Abstract][Full Text] [Related]
17. Memory modification as an outcome variable in anxiety disorder treatment. Tryon WW; McKay D J Anxiety Disord; 2009 May; 23(4):546-56. PubMed ID: 19117720 [TBL] [Abstract][Full Text] [Related]
18. Alprazolam (Xanax, and others) revisited. Med Lett Drugs Ther; 2005 Jan; 47(1200):5-7. PubMed ID: 15647704 [TBL] [Abstract][Full Text] [Related]
19. Enhancing prolonged exposure therapy for posttraumatic stress disorder with D-cycloserine: further support for treatments that promote experience-dependent neuroplasticity. Krystal JH Biol Psychiatry; 2012 Jun; 71(11):932-4. PubMed ID: 22579302 [No Abstract] [Full Text] [Related]
20. [The influence of alprazolam on the symptoms of anxiety and depression]. Małyszczak K; Kiejna A Psychiatr Pol; 1997; 31(6):745-52. PubMed ID: 9515306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]